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Infrared Thermography to Assess Proliferation
and Involution of Infantile Hemangiomas
A Prospective Cohort Study
Javed Ayoub Mohammed, MD; Alexandra Balma-Mena, MD; Ajith Chakkittakandiyil, MD; Florentina Matea, MD; Elena Pope, MD

IMPORTANCE Infantile hemangiomas (IHs) are common benign tumors of infancy that have
the potential to interfere with vital organ function and cause permanent disfigurement.
Currently, few objective and validated measures exist to assess IHs.
OBJECTIVE To determine the utility of infrared thermography in assessing and monitoring the
growth of IHs.
DESIGN, SETTING, AND PARTICIPANTS In a prospective cohort study conducted at an
outpatient dermatology clinic of a tertiary care hospital between February 2011 and
December 2012, a convenience sample of 42 infants aged 0 to 6 months with an IH were
enrolled. The mean age of the study group was 3.7 months, with the majority of IHs being
mixed type (57%) affecting the head and neck (81%). Of the infants, 36 (86%) were receiving
active treatment during the study period, and patients were followed for a minimum of 3
clinical visits, at least 1 month apart.
MAIN OUTCOMES AND MEASURES Ability of infrared thermography to assess the proliferation
and involution of IHs compared with a visual analog scale. Secondary outcomes were
reliability, ease of use, and parental acceptance of the instrument.
RESULTS The mean temperature difference at baseline was 1.9°F (95% CI, 1.2°F to 2.7°F),
which peaked at 3 months to 2.5°F (95% CI, 0.8°F to 4.2°F), and decreased progressively to
0.2°F (95% CI, −1.1°F to 1.4°F) at 18.5 months (P < .001). This change in temperature was
inversely correlated with mean visual analog scale (r = −0.25). Mean temperature differences
recorded at baseline and 30 minutes later were not significant (least squares mean baseline
temperature, 87.9°F [95% CI, 87.4°F to 88.3°F], vs least squares mean temperature after 30
minutes, 88.1°F [95% CI, 87.7°F to 88.6°F] [P = .14]). Multivariate analysis demonstrated
facial location (F1,365 = 47.63, P < .001), IH type (F2,365 = 3.26, P = .04), age (F2,365 = 7.03,
P = .001), and surface area at baseline (F2,365 = 8.18, P < .001) as factors significantly
affecting temperature difference over time. Only IH type (Wald χ 22 = 6.79, P = .03) and
treatment (Wald χ 12 = 4.29, P = .04) significantly affected time to reach a zero-temperature
difference. All caregivers (100%) reported IRT to be easy to implement, quick to perform, and
comfortable for their child.
CONCLUSIONS AND RELEVANCE Infrared thermography is a reliable and valid measure of IH
growth that is noninvasive, convenient, and well tolerated by infants, making it well suited to
daily clinical practice. It has the potential to provide real-time objective results that can be
used for routine monitoring and evaluating treatment efficacy.
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I

nfantile hemangiomas (IHs) are the most common benign
tumors of infancy, affecting nearly 10% of children.1,2 Their
clinical presentation can vary significantly, from small superficial papules to large tumors that can interfere with vital
organ function and/or cause permanent disfigurement. The
natural history of IHs is characterized by proliferation and slow
involution over several years.2 Accurate assessments of where
on the proliferation-involution curve a particular IH lies, at any
given time, is important in both making appropriate treatment recommendations, as well as evaluating treatment efficacy. Despite its importance, routine assessment of IHs has
largely remained unchanged for decades, often relying solely
on the physician’s subjective assessment of color, size, tenseness, and temperature.
Currently, few objective and validated measures exist to assess IHs. Visual analog scales (VAS) have been widely used in
the literature to measure the change in the size and extent of
IHs.3-6 Several mathematical formulas using measured parameters have been proposed to be accurate estimates of IH volume, but none have proven ideal for all types.7-9 Other modalities such as ultrasonography10,11 and various imaging techniques
are not always practical for routine clinical assessments.
Both physicians and parents report that surface temperature tends to correlate with IH growth; the proliferative phase
is characterized by increased tactile local temperature with normalization during involution. Its major limiting factor has been
the lack of a quantifiable and convenient tool that can measure these temperature changes in the clinical setting. Recently, infrared thermography (IRT) has been shown to be an
objective measure of local temperature differences and a safe
and useful method to evaluate several thermal-related pathologic states.12 Infrared thermography has been used in the assessment of vascular malformations and burns, as well as digit
reimplantation and prediction of diabetic foot ulcers.12-14 However, its use in IHs has been limited to date, with only a few
studies reporting its use.12,15,16 The purpose of the present study
was to examine the clinical utility, reliability, and validity of
IRT in monitoring the growth pattern of IHs.

Methods
The study protocol was approved by the Hospital for Sick Children Research Ethics Board, Toronto, Ontario, Canada. Written informed consent was obtained from the infants’ parents
prior to inclusion in the study. This prospective cohort study was
conducted between February 2011 and December 2012 at the
Dermatology Department at the Hospital for Sick Children, Toronto, a tertiary academic referral center. Infants with an IH diagnosed between the ages of 0 and 6 months, with a minimum
of 3 follow-up visits at least 1 month apart, were included. Exclusion criteria were mid-line lesions (due to inability to select
a nonaffected contralateral side) and ulcerated, secondarily infected, or actively bleeding IH. Age and sex were recorded for
each patient, as well as the clinical characteristics of the IH including type (superficial, deep, or mixed), location, and surface area. Photographic documentation was performed for all
IHs at each visit. The procedure for acquiring photographs was
jamadermatology.com
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standardized through written guidelines. Data on the ease of administration of IRT, perception of invasiveness, and time to measure the temperature were collected using a structured questionnaire administered to parents.
The local temperature of each IH was independently measured by a research assistant using the TempTouch digital IRT
device (Diabetica Solutions Inc). Several studies demonstrated its utility in reducing the incidence of diabetic foot ulcers by monitoring skin temperature.13,14 This thermographic
device has a “gooseneck”-designed probe, allowing for easy access to nearly all anatomical locations. The probe is touched to
the surface of the IH, and after a few seconds of contact it automatically displays the temperature on a digital screen. The device measures the temperature in Fahrenheit, and as a result
these units were used for all subsequent analysis. For IHs with
a width (measured across the lesion) of 3.99 cm or less, a single
reading was taken from the center of the IH. For an IH with a
width of 4 cm or greater, 2 readings were taken, one from the
central region and one from the periphery of the IH. These values were chosen based on the IRT probe having a diameter of
1.5 cm. Infrared thermography was also used to measure the
temperature from the contralateral nonaffected side to obtain
a temperature difference, similarly to previous studies using this
thermographic device.13,14 In addition, a temperature reading
was performed 30 minutes from the first measurement to test
reliability. This method was used at the first baseline visit and
at all subsequent visits, which were typically within 2 months
of each other. Patients were included in the final data analysis
if they had a baseline visit and at least 2 follow-up visits.
The primary outcome of the study was to examine the ability of IRT to assess the proliferation and involution of IHs as
evaluated using a VAS. The VAS uses a 100-mm scale, where
−100 represents a doubling in the size and extent of the IH; 0,
no change, and +100, complete resolution (therefore, 5 mm reflects a 10% change). One assessor (J.A.M.), blinded to the temperature readings, reviewed all pictures at the end of the study
and provided a VAS score at each visit by comparing each follow-up visit photograph with baseline in terms of size and extent. The temperature difference (temperature of the IH minus temperature of the contralateral side) for each patient was
compared with the changes in the VAS over time.
Descriptive statistics were used to summarize the data. For
the primary outcome, the correlation (r) between investigator VAS and temperature difference was calculated. Analysis
of variance was used to compare initial and 30-minute temperature differences. To ascertain factors affecting temperature difference over time, a multivariate analysis using temperature as a continuous variable was used. Factors affecting
time to zero-temperature difference were calculated using a
multivariate log-logistic regression analysis. Statistical significance was set at P < .05. All analyses were performed using SAS
9.2 (SAS Institute Inc).

Results
Forty-two infants were enrolled, with the majority being female (n = 35 [83%]). The mean (SD) age at enrollment was 3.7
JAMA Dermatology September 2014 Volume 150, Number 9
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Figure. Change in Mean Temperature Difference as Measured by Infrared Thermography
and Mean VAS Score With Age
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Table. Multivariate Analysis of Factors Affecting Time to Reach a Zero-Temperature Difference Between
Contralateral and Affected Sides

Characteristic

No. of IHs

Median Months to
Zero-Temperature
Difference

P Value

Treatment
Yes

36

3.4

No

6

9.4

.04

Facial location
Yes

27

3.4

No

15

7.3

.18

IH type
Superficial

14

7.8

Deep

4

0.7

Mixed

24

3.4

1-2

7

7.4

3-4

18

4.5

≥5

17

7.6

≤1.75

11

7.1

>1.75 and ≤7.0

11

3.3

>7.0

12

4.1

.03

Age at baseline, mo

.34

Surface area at baseline, cm2

(1.36) months. The most common location was the head and
neck area (n = 34 [81%]), followed by the trunk (n = 3 [7%]), extremities (n = 3 [7%]), and genital area (n = 2 [5%]). Mixed IHs
(superficial and deep components) were the predominant type
(n = 24 [57%]), with the least common being deep type (n = 4
[10%]). Most patients (n = 36 [86%]) were receiving treatment
during the study, which included propranolol hydrochloride
(n = 20 [56%]), nadolol (n = 6 [17%]), timolol maleate gel, 0.5%
(n = 5 [14%]), and combination treatment (n = 5 [14%]).
The mean temperature difference at baseline was 1.9°F
(95% CI, 1.2°F to 2.7°F), which peaked at 3 months to 2.5°F (95%
CI, 0.8°F to 4.2°F). This was followed by a plateau between 8
to 12 months after which the temperature decreased progressively to 0.2°F (95% CI, −1.1°F to 1.4°F) at 18.5 months (P < .001)
(Figure). The mean VAS score increased progressively over the
same period and was inversely correlated with mean tempera966

.23

ture difference (r = −0.25) (Figure). A multivariate analysis
demonstrated facial location (F1,365 = 47.63, P < .001), IH type
(F2,365 = 3.26, P = .04), age (F2,365 = 7.03, P = .001), and surface area at baseline (F2,365 = 8.18, P < .001) as factors affecting temperature difference over time. In an analysis of variables affecting time to reach a zero-temperature difference,
between the affected and contralateral side, only IH type (Wald
χ 22 = 6.79, P = .03) and treatment (Wald χ 12 = 4.29, P = .04) were
significant (Table). Receiving active treatment was associated with less time to reach a zero-temperature difference. At
18 months, 32 of 36 treated IHs (89%) reached a zerotemperature difference vs 3 of 6 untreated IHs (50%). For IH
types, deep IHs required the least amount of time to reach a
zero-temperature difference, followed by mixed and superficial IH. All deep (4 of 4) and superficial (14 of 14) IHs had zerotemperature difference at 18 months vs 17 of 24 mixed IHs (72%)
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To assess reliability of the IRT, IH temperature assessments were repeated 30 minutes after the initial reading. The
mean temperature difference between these 2 time points was
not significant (least squares mean baseline temperature, 87.9°F
(95% CI, 87.4°F to 88.3°F) vs least squares mean temperature
after 30 minutes, 88.1°F (95% CI, 87.7°F to 88.6°F) (P = .14).
The results of the parent questionnaire revealed that of the
38 of 42 parents who completed the survey, 38 (100%) believed that IRT was an easy method to implement, with no parents disclosing any inconveniences of the tool. Similarly they
reported that it took less than 30 seconds to measure the temperature and no parent expressed concerns about the child’s
discomfort during the testing.

Discussion
In this prospective study, IRT was demonstrated to be an objective and reliable method for assessing the proliferation and
involution of IHs. It was also found to be a convenient and noninvasive technique that is well tolerated by patients and easily implemented into routine clinical practice.
Infantile hemangiomas are clinically heterogeneous, making it difficult to adequately quantify the size of one particular lesion and to monitor progression over time. At present, a
standardized method for assessing the growth of IHs is lacking. Few modalities exist that are objective, reliable, and validated for every day clinical practice. Visual analog scale has
been widely used as an objective measure,3-6 but its validity
is dependent on the quality of the picture and it is subject to
intrapersonal and interpersonal variability. Several reports have
proposed estimating the volume of IHs using mathematical formulas based on measured parameters. Both Tsang et al7 and
Dixon et al8 described formulas for estimating the volume of
IHs through assuming their shapes as perfect or half spheres.
A third more versatile method has been developed that accurately measures the volume of ellipsoid IHs, not accounted for
by the aforementioned formulas, and is as accurate in measuring spherical IHs.9 Although these methods can be performed at the bedside, no one formula is universally applicable to all IH shapes, and none measure the volume of IHs
below the skin.7-9 Furthermore, they all require taking precise measurements from an active infant and at times from difficult to access anatomical areas. Most recently, grading scales
that attempt to standardize the severity of IHs and its complications have been developed for longitudinal use.17 These have
been shown to have good reliability, but they were not designed to provide information with regard to IH volume and
extent.17 Imaging such as ultrasonography and magnetic resonance imaging have also been used to objectively measure IH
growth and involution. Several studies have used ultrasonography to measure IH thickness, as well as resistivity index, as
a measure of blood flow to follow IH regression.11,18,19 However, the objectivity and reliability of the resistivity index has
been questioned by some authors owing to high variability and
dependency on the activity of the patient.11 Its everyday clinical use is further limited by interoperator variability11,20,21 and
the need for an experienced ultrasonographer. In addition,
jamadermatology.com
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painful ulcerated IHs and certain anatomical locations are not
amenable to acquiring a sufficient ultrasound study, particularly in young, active children.11,19 In a study by Schiestl et al11
examining the efficacy of propranolol to treat IHs, only 11 of
the 25 patients studied had technically sufficient ultrasound
studies.11 Magnetic resonance imaging may provide an assessment of the volume and extent of IH,22,23 but its cost, need for
sedation in young children, and limited availability precludes its routine use for monitoring of the progression of IHs.
Magnetic resonance imaging use is largely limited to the diagnosis, evaluation, and progression of extracutaneous IHs.24
The use of IRT in the assessment of IH growth has been
scarcely reported since it was first described in 1975 in a heterogeneous population of IHs and vascular malformations.15 Subsequently, Desmons et al,16 in a study of 25 IHs and IRT, reported
a temperature difference of greater than 0.5°C between the IH
center and the surrounding or contralateral skin in 92% of the
IHs studied. Most recently, IRT was used to follow the clinical
progression of 32 cutaneous IHs.12 Consistent with our findings,
both studies reported a decrease in the temperature difference
over the course of the studies, although the specific data, including patient ages and follow-up times, were not provided.12,16
In addition, the temperature change observed over time in the
present study was closely correlated with previous studies describing IH growth characteristics.25 The peak temperature difference was achieved at 3 to 4 months of age, the period during which the most rapid proliferation of IHs is known to occur,
while a steady decrease in temperature was noted starting at
12 months of age, when most IHs begin to involute.25 The changing temperature in IHs is thought to reflect changes in blood flow
with ongoing proliferation characterized by increasing blood
flow and involution characterized by a reduced blood flow secondary to endothelial cell apoptosis. The changes in blood flow
lead to varying degrees of transmitted infrared radiation, which
is detected by the IRT device.12,15,16 Interestingly, as some IHs
neared almost complete involution, a negative temperature difference was detected (data not shown). These results suggest
that the fibrofatty tissue that replaces tumoral tissue may be less
well perfused than normal skin. Alternatively, this finding may
reflect the fact that residual fibrofatty tissue, particularly from
those resulting from mixed IH, may be farther from the body,
leading to a reduced surface temperature.
Several factors were demonstrated to influence temperature change over time including facial location, IH type, age,
and surface area at baseline. It has been well described that superficial IHs have a shorter growth phase than deep IHs,25 while
clinically smaller IHs are often observed to involute more rapidly, potentially owing to their smaller volume. The influence
of age at baseline may relate to its impact on the timing of the
presentation before or after the peak temperature difference
and as a result the overall temperature difference. We also examined variables affecting time to reach a zero-temperature
difference because this was believed to be the best outcome
measure correlating with significant clinical IH involution. In
this analysis, only IH type and treatment were found to be significant. As expected, receiving active treatment was associated with a reduced time to zero-temperature difference. Of
the IH types, deep IHs required the least amount of time to
JAMA Dermatology September 2014 Volume 150, Number 9
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reach this outcome. This may have been secondary to the small
sample size and thus needs to be interpreted with caution. Interestingly, the median time required to reach a zerotemperature difference for mixed IHs was less than for superficial IHs. However, a higher percentage of patients with
superficial IHs (100%) vs mixed IHs (72%) achieved this end
point at 18 months of age, reflecting the quicker overall involution of superficial IHs often observed in clinical practice.
As a tool to evaluate IH growth, IRT has several advantages. It is time efficient, safe, painless, and practical for monitoring IHs at virtually any cutaneous location. Most importantly, it was well accepted by parents as a noninvasive
assessment tool and was well tolerated by infants. Saxena and
Willital12 reported similar findings in a 10-year review of IRT
in various pediatric conditions including IHs, vascular malformations, burns, wound infections, and digit amputations.
These characteristics make IRT an ideal tool for making treatment related decisions at the bedside, in addition to providing an objective measure of IH involution in treatment intervention studies, an area currently lacking a readily available
and noninvasive objective outcome tool. Infrared thermography in conjunction with clinical assessments may be able to
better reassure parents that a particular IH is involuting, possibly avoiding unnecessary β-blocker treatment and parental
anxiety. Likewise, IRT provides a temperature trend over time
that has the potential to detect treatment failures, identify rebound growth earlier, and improve treatment related end
points such as timing of β-blocker weaning and cessation. This
is supported by a recent pilot study from our center that demonstrated IRT to be a useful tool to measure therapeutic response to a systemic β-blocker.26 Most promisingly, IRT has the
advantage of potentially detecting all such changes before they
are appreciated clinically; however, this requires further study.
Its application to other vascular tumors such as congenital hemangiomas and hemangioendotheliomas also requires further
investigation.
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Several limitations of the study need to be considered.
Imaging studies would have provided a more objective independent measure of IH growth; however, this was not feasible given the time needed and frequent follow-up required.
For this reason, VAS was used because it is noninvasive, can
be applied to all IH types, and is a well-accepted measure of
growth in IH treatment trials. Although it was demonstrated
that IRT can be used for monitoring all IH types at various locations, midline IHs were excluded because they do not have
a corresponding contralateral area of normal skin from which
to measure the temperature difference. Several studies have
shown that the surrounding skin can be used, but this was not
evaluated in the present study.15,16 Ulcerated, bleeding, and infected IHs were also excluded because these may have caused
false temperature elevations that were not truly reflective of
increased IH growth. In theory, these IHs could be followed
with IRT, which may have the additional advantage of detecting ulcerations before they occur clinically and monitoring their
resolution. This is supported by evidence from adult studies
in which IRT has been proven to reduce diabetic ulcerations
through detection of asymptomatic inflammation. The application to ulcerated IHs requires further evaluation.

Conclusions
With the emergence of newer and safer treatments for IHs, it
has become increasingly important to have a standardized objective measure of growth. The present study demonstrates
that IRT is a reliable and valid measure of IH growth that is well
adapted to the clinical setting. It has the potential to provide
the clinician with real-time results from which management
decisions can be made and treatment efficacy evaluated. Future studies are required to evaluate IRT in relation to other
objective measures of IH growth, as well as to assess its applicability in complicated IHs.
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NOTABLE NOTES

Carlo Forlanini, the Dermatologist Who Invented the Cure for Pulmonary Tuberculosis
Filippo Pesapane, MD; Antonella Coggi, MD; Raffaele Gianotti, MD

Carlo Forlanini was born in 1847 in Milan, Italy, and was the son of Federico Forlanini, the primary doctor from Milan’s Fatebenefratelli Hospital. Carlo was the elder brother of Enrico Forlanini, an inventor and aeronautical pioneer well known for his works on helicopters, aircraft,
hydrofoils, and dirigibles. Forlanini joined the faculty of medicine at the
University of Pavia. In 1866, he volunteered to serve under Giuseppe
Garibaldi, and in 1870 he graduated with a thesis focused on cutaneous
inflammation entitled “Contribuzione alla Teoria della Piogenesi.”1 A close
friend in his student days was Camillo Golgi, a man who would later
achieve eminence as a histologist and receive the Nobel Prize in 1906.2
Milan's main hospital, “Ospedale Maggiore Policlinico” (now “Fondazione Ca’ Granda”), attracted Forlanini, and he was accepted in 1871. He
spent the next 13 years working in the departments of chronic diseases, eye diseases, and, particularly, skin diseases. In January 1876, he
was appointed the head of the skin department, a post he would retain
for the next 6 years in order to continue his interest in studying
tuberculosis.1
In the 1882, the same year that Robert Koch discovered of the tubercle bacillus, Forlanini introduced a new treatment of pulmonary tuberculosis: the artificial pneumothorax. He based this treatment on the
intuition that to heal from lung tuberculosis it was necessary suppress
its function, or rather to collapse it to eliminate the respiratory trauma.
The method is based on the technique of “collassoterapia,” which Forlanini also invented. The technique consists of introducing inert gas into
the pleural cavity corresponding to the injured lung so that it is placed
in a state of functional rest to facilitate healing.3 For some 40 years before the introduction of antituberculous drugs, artificial pneumothorax
offered hope and, in many cases, healing to patients with tuberculosis
around the world.
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In 1884, he was appointed chair of Clinica Propedeutica at Turin, Italy,
and, finally, in 1900 he obtained the chair of clinical medicine at the University of Pavia, an institution that boasted a glorious tradition. This was
where Giulio Bizzozero had made discoveries on the physiologic characteristics of blood, where Paolo Mantegazza had signaled the importance of the glands of internal secretion, and where Edoardo Bassini had
developed his method of treating inguinal hernia.2 By all accounts, Forlanini was a popular teacher. Among his pupils was Scipione RivaRocca, who introduced the first practical sphygmomanometer in 1896.1
In 1913, Forlanini became a senator of the Italian Republic, and at the
time of his death in 1918 he had been proposed for the Nobel Prize in
Medicine. After his death, a research fund for the study of tuberculosis
was created in his name. In 1934, the “Carlo Forlanini Institute” was
founded in Rome, comprising a complex of sanatorium, university clinic,
laboratories museum, and research center.1
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